NCT06567353Recruiting
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
Source: ClinicalTrials.gov · Last updated 14 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 20 Aug 2024
- Start date
- Dec 2024
- Primary completion date
- Jul 2027
- Lead sponsor
- Ruijin Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06567353
What you commit to
- Study type: Interventional
- Planned participants: 10
- From Dec 2024 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously participated in other clinical studies and still within the follow-up period;
Other illness
- History of esophageal (gastric fundus) variceal bleeding within the past month;
- Dysfunction or failure of vital organs;
- Presence of an active infection;
Other
- Liver function Child-Pugh class C;
- Systemic widespread metastasis, with an expected survival of \< 3 months;
- Irreparable coagulation abnormality;
- Refractory massive ascites, pleural effusion or cachexia;
- Pregnancy, altered consciousness or patients unable to cooperate with treatment;
- Any other factors deemed inappropriate for inclusion or that may affect the patient's participation in the study, as determined by the investigator.
Who the study is looking for
- Age 18-75 years, female gender;
- Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection;
- The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm;
- At least an interval of 1 month since the last local treatment;
- Child-Pugh class A or B;
- ECOG PS score ≤2, with an expected survival of \>3 months.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.